Aurobindo Pharma gets USFDA EIR for Telangana facility

Published On 2023-09-08 05:00 GMT   |   Update On 2023-09-08 05:00 GMT

Hyderabad: Aurobindo Pharma has announced that the company has received an Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) classifying the Company’s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana as "Voluntary Action Indicated" ("VAI").VAI means objectionable conditions...

Login or Register to read the full article

Hyderabad: Aurobindo Pharma has announced that the company has received an Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) classifying the Company’s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana as "Voluntary Action Indicated" ("VAI").

VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

USFDA had inspected the the said facility from July 14 to July 21, 2023 and issued Form 483 with 3 observations.

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over multiple therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Read also: USFDA tentative nod to Aurobindo Pharma's generic FDC drug to treat HIV in children

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News